Enfermedad de Alzheimer y diabetes mellitus, ¿enfermedad neuroendocrina?

1. Zaida R Santana-Rodríguez ¹
2. Luis G. Hernández-Abad ¹
3. Ibrahim González Marrero ¹

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Majorensis: Revista Electrónica de Ciencia y Tecnología

Abstract

This paper focuses on studying Alzheimer's disease (AD) as a neuroendocrine disease, as there is evidence to show that people with type 2 (DMT2) or type 1 (DMT1) diabetes have a higher risk of developing AD than people without it. Many researchers, especially the scientist Suzanne La Monte, who called AD "Diabetes Mellitus type 3". This name is due to the fact that patients with AD have characteristics of these two pathologies, especially type 2 diabetes. So, it has also been shown that drugs used for the treatment of this disease are yielding beneficial results for AD.

Data source: Dialnet